Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: D. Cella, B. Escudier, B. I. Rini, C. Chen, H. Bhattacharyya, J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2306983940